Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomised controlled trial
- 1 February 2001
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 357 (9255) , 509-512
- https://doi.org/10.1016/s0140-6736(00)04042-3
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studiesThe Lancet, 2001
- Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trialsThe Lancet, 2001
- HMG-CoA Reductase Inhibitors and the Risk of FracturesJAMA, 2000
- HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly PatientsJAMA, 2000
- Oral statins and increased bone-mineral density in postmenopausal womenThe Lancet, 2000
- Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older womenThe Lancet, 2000
- Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate SynthaseArchives of Biochemistry and Biophysics, 2000
- Stimulation of Bone Formation in Vitro and in Rodents by StatinsScience, 1999
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including RasJournal of Bone and Mineral Research, 1998